Unicycive Therapeutics, Inc.
$7.43
▼
-2.67%
2026-04-21 10:02:00
unicycive.com
NCM: UNCY
Explore Unicycive Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$177.17 M
Current Price
$7.43
52W High / Low
$11 / $3.71
Stock P/E
—
Book Value
$1.36
Dividend Yield
—
ROCE
-97.75%
ROE
-1.41%
Face Value
—
EPS
$-1.67
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
21
Beta
1.8
Debt / Equity
0.39
Current Ratio
2.58
Quick Ratio
2.59
Forward P/E
0.77
Price / Sales
—
Enterprise Value
$126.17 M
EV / EBITDA
-4.28
EV / Revenue
—
Rating
Strong Buy
Target Price
$39.89
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | SAB Biotherapeutics, Inc. | $3.86 | 14.78 | $196.16 M | — | -30.19% | 14.96% | $6.6 / $1.3 | $3.18 |
| 2. | Cue Biopharma, Inc. | $0.85 | — | $82.97 M | — | -92.35% | -121.11% | $1.03 / $0.17 | $0.27 |
| 3. | BridgeBio Pharma, Inc. | $74.02 | — | $14.41 B | — | -77.47% | 40.79% | $84.94 / $31.77 | $-10.71 |
| 4. | Lantern Pharma Inc. | $2.76 | — | $27.91 M | — | -275.14% | -1.24% | $5.74 / $1.11 | $0.58 |
| 5. | ArriVent BioPharma, Inc. | $31.39 | — | $1.31 B | — | -57.79% | -58.88% | $30.72 / $16.1 | $7.24 |
| 6. | Atara Biotherapeutics, Inc. | $4.99 | 1.29 | $42.24 M | — | 674.99% | -48.15% | $19.14 / $3.92 | $-5.26 |
| 7. | Tenax Therapeutics, Inc. | $14.1 | — | $247.99 M | — | -58.09% | -55.64% | $18.38 / $4.63 | $2.29 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -7.22 M | -7.34 M | -6.96 M | -7.99 M | -9.26 M | — |
| Net Profit | -14.67 M | -6.01 M | -6.45 M | 0.57 M | -21.52 M | — |
| EPS in Rs | -0.58 | -0.24 | -0.26 | 0.02 | -0.85 | -0.46 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0.68 M | 0.95 M |
| Operating Profit | -29.52 M | -32.12 M | -20.77 M | -18.05 M |
| Net Profit | -26.55 M | -36.73 M | -30.54 M | -18.06 M |
| EPS in Rs | -1.05 | -1.46 | -1.21 | -0.72 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 49.13 M | 31.67 M | 14.19 M | 2.82 M |
| Total Liabilities | 18.94 M | 24.24 M | 18 M | 3.28 M |
| Equity | 30.2 M | 7.43 M | -3.81 M | -0.47 M |
| Current Assets | 48.96 M | 30.95 M | 13.4 M | 2.64 M |
| Current Liabilities | 18.94 M | 24.12 M | 17.53 M | 3.28 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -31.32 M | -28.57 M | -18.28 M | -15.65 M |
| Investing CF | -12.1 M | -0.07 M | -0.01 M | -0 M |
| Financing CF | 46.47 M | 45.09 M | 27.54 M | -0.47 M |
| Free CF | -31.34 M | -28.65 M | -18.3 M | -15.65 M |
| Capex | -0.02 M | -0.07 M | -0.01 M | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | -29.02% | — | — |
| Earnings Growth % | -20.25% | -69.14% | — | — |
| Profit Margin % | — | -4525.04% | -1898.84% | — |
| Operating Margin % | — | -3077.63% | -1898.21% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | -4470.81% | -1881.28% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-20 | 1:0.1 |